Stock Updates

A look at a High Market Cap Stock: Teva Pharmaceutical Industries Limited, TEVA

Teva Pharmaceutical Industries Limited, TEVA is in the exchange NYSE and its industry is Drug Manufacturers РOther in the sector of Healthcare. Based in Israel, Teva Pharmaceutical Industries Limited, TEVA  has a market cap of 50265.8. Since its IPO date on the 3/26/1990, Teva Pharmaceutical Industries Limited, TEVA performance year to date is -17.35%. Today Teva Pharmaceutical Industries Limited, TEVA has gained 3.29%, with a current price of 55.33.

Ownership of the company is 2.70% for insider ownership while institutional ownership is 66.00%. The management of the company have seen the company have a payout ratio of 70.10%. Return of assets are at 3.30%, with return on investment at 5.70%.

In terms of debt levels and profit levels, Teva Pharmaceutical Industries Limited, TEVA is seeing a long-term debt/equity of 0.28. While Total debt/equity is 0.34. With a profit margin of 8.70%, this is combined with a gross margin of 58.10%, and operating margin of 19.30%. Teva Pharmaceutical Industries Limited ability to meet debt levels, with a current ratio of 1.3, while the quick ratio is 1.

For the last year Teva Pharmaceutical Industries Limited, TEVA has seen a EPS growth of -48.90%. A performance for the year of -22.42%. The 52-week high is -20.98%, and the 52-week low is 15.25%. The average volume for Teva Pharmaceutical Industries Limited, TEVA is 4572569.

With a target price of 70.7, can Teva Pharmaceutical Industries Limited, TEVA reach this target? Looking at the value indicators of Teva Pharmaceutical Industries Limited, TEVA. Teva Pharmaceutical Industries Limited has a P/E of 27.89 and a forward P/E of 8.92. Perhaps the more useful indicator than P/E, is PEG which has a value of 5.33. Teva Pharmaceutical Industries Limited also has a P/S and a P/B of 2.58 and 1.61 respectively. For P/cash, Teva Pharmaceutical Industries Limited has a value of 8.43, while it is *TBA for P/free cash flow.

At the current price of 55.33, Teva Pharmaceutical Industries Limited has a dividend yield of 2.54%. We see a return on equity of 6.60%.

Looking more long-term Teva Pharmaceutical Industries Limited, is projected to get an EPS growth for the next five years of 5.23%. In the short-term an EPS growth of 13.28% in the next year is forecasted. This is after a EPS growth of -48.90% for this year and for the last five years a -13.10% growth has been seen.

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.

About the author

Stephen Butters

Leave a Comment